Treatment with Rasilez HCT had an overall incidence of adverse experiences at doses up to 300 mg/ 25 mg similar to placebo.
Annuste kuni 300 mg/ 25 mg kasutamisel oli Rasilez HCT kõrvaltoimete üldine esinemissagedus sarnane platseeboga.